We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
Cap. Flow
+$9.23M
Cap. Flow %
6.1%
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.74M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.78M
3
GILD icon
Gilead Sciences
GILD
+$3.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.72M
5
MRK icon
Merck
MRK
+$2.59M

Top Sells

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$4.35M
2
CPHD
Cepheid Inc
CPHD
+$4.07M
3
AZN icon
AstraZeneca
AZN
+$2.85M
4
BIIB icon
Biogen
BIIB
+$2.01M
5
MTD icon
Mettler-Toledo International
MTD
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Miscellaneous 14.74%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$177M
$541K 0.36%
+383
New +$667K
2015 Q4
0 quarters
SRRA
52
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$451K 0.3%
+750
New +$507K
2015 Q4
0 quarters
SIOX
53
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$340K 0.22%
2,357
-1,483
-39% -$193K
2015 Q3
1 quarter
PLXP
54
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$280K 0.19%
+3,125
New +$300K
2015 Q4
0 quarters
INFI
55
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$236K 0.16%
30,000
-15,300
-34% -$132K
2015 Q2
2 quarters
KALV icon
56
DELISTED
KalVista Pharmaceuticals
KALV
$63K 0.04%
+1,250
New +$65.4K
2015 Q4
0 quarters
ARWR icon
57
Arrowhead Research
ARWR
$8.03B
– –
-51,133
Closed -$295K –
ASMB icon
58
Assembly Biosciences
ASMB
$407M
– –
-1,250
Closed -$143K –
CRIS icon
59
Curis
CRIS
$968K
– –
-187
Closed -$756K –
LABU icon
60
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$530M
– –
-186
Closed -$241K –
TECH icon
61
Bio-Techne
TECH
$11.4B
– –
-188,000
Closed -$4.35M –
TLPH icon
62
Talphera
TLPH
$56.6M
– –
-2,887
Closed -$176K –
XBI icon
63
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.59B
– –
-862,500
Closed -$53.7M –
CMRX icon
64
DELISTED
Chimerix, Inc.
CMRX
– –
-14,152
Closed -$541K –
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-75,000
Closed -$662K –
ARRY icon
66
DELISTED
Array Biopharma Inc
ARRY
– –
-250,000
Closed -$1.14M –
CPHD
67
DELISTED
Cepheid Inc
CPHD
– –
-90,000
Closed -$4.07M –
XNPT
68
DELISTED
XENOPORT, INC.
XNPT
– –
-40,000
Closed -$139K –
NHLD
69
DELISTED
National Holdings Corporation
NHLD
– –
-89,530
Closed -$246K –
RPRX icon
70
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-98,000
Closed -$494K –
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.

  • Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
  • Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
  • Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
  • Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
  • Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
  • Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.

Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.